A leading Polish medical university has designed a pharmaceutical composition containing roxithromycinfor to be used as a medicinal product for the treatment of androgenetic alopecia and/or acne vulgaris.
Treatment of acne vulgaris and androgenetic alopecia is a difficult and long-lasting process. In the treatment of androgenogenic alopecia, the only approved formulation for topical use by the Food and Drug Administration is 2% and 5% Minoxidil. On the other hand, this substance is suitable for oral therapy, but it is associated with serious side effects and only men can be treated with it. There are no alternative pharmacological agents typically applied in the therapy for alopecia. Acne vulgaris is one of the most common dermatoses and despite the fact that many pharmaceuticals are available in the pharmaceutical market to combat it, more effective and innovative solutions are still sought after.
Roxithromycin is an antibiotic from the group of semi-synthetic macrolides. It is a 10-oxy-ether derivative of erythromycin with increased acid resistance and better pharmacokinetic parameters. It is a lipid type of compound. It is used orally in the treatment of Gram-positive infections, less often Gramnegative infections. Its mechanism of action consists of blocking the biosynthesis of bacterial proteins. In addition to the typically antimicrobial activity, roxithromycin also inhibits the production of proinflammatory compounds by bacteria that contribute to the development of acne. There have also been reports of roxithromycin inhibition of free radical formation in neutrophils and inhibition of keratinocyte apoptosis.
An innovative pharmaceutical composition containing roxithromycin has been developed which can be used for example for the treatment of androgenetic alopecia and/or acne vulgaris. In order to produce the proposed preparation, lipid micro- and nanoparticles were used as carriers of roxithromycin for hair follicles.
The university is offering to sell license/IP rights for the composition of this medicinal product to a foreign partner. The substance must undergo clinical trials in order to be authorised for the market. Potential partner would have to create branding and visual identification of the market-ready product.